J. Goldman & Co’s Protalix BioTherapeutics PLX Stock Holding History

J. Goldman & Co’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,330	Closed	-$25K	–	325
2019 Q3	$25K	Sell	12,330 -37,670	-75%	-$112K	﹤0.01%	270
2019 Q2	$235K	Buy	+50,000	New	+$211K	0.02%	247

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

J. Goldman & Co's PLX Position: Q4 2019 in Review

J. Goldman & Co sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 12,330 shares — an estimated $25K sold.

J. Goldman & Co first reported a position in PLX in Q2 2019 and held it in 2 quarters. The position peaked at $235K in Q2 2019. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

J. Goldman & Co reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
J. Goldman & Co sold 12,330 Protalix BioTherapeutics shares in Q4 2019, an estimated $25K.
J. Goldman & Co first reported a position in Protalix BioTherapeutics in Q2 2019 and held it in 2 quarters.
J. Goldman & Co's Protalix BioTherapeutics position peaked at $235K in Q2 2019.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on J. Goldman & Co's 13F filing for Q4 2019, filed 14 Feb 2020.